Archynetys Live news trend intelligence
↓ Cooling Business 🔮 Archynetys predicts: fades by tomorrow

FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class

FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.

8sources
8articles
6velocity
-60%since first seen
9h agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

75/100 Excellent
8distinct sources shown
10velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected

  2. Peak measured velocity

  3. Evidence threshold reached

  4. Latest coverage observed

Momentum

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

What happened

⚡ Executive Intelligence Takeaways Corroborated across 8 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 8 distinct news outlets with 8 published articles, achieving a live velocity of 6.
  • Primary Driver: FDA rejects Summit's ivonescimab, halting the first PD-1xVEGF bispecific antibody from reaching the US market.
  • Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

The US Food and Drug Administration declined to approve ivonescimab, a bispecific antibody targeting PD-1 and VEGF developed by China's Akeso and licensed to Summit Therapeutics, for a narrow lung cancer indication. Summit disclosed the complete response letter in a regulatory filing, stating the agency determined the HARMONi-2 trial missed its key overall survival endpoint in the intended population.

Reuters and STAT confirm the rejection centered on the trial's failure to demonstrate a statistically significant survival benefit, while Endpoints News notes the decision applies specifically to the narrow setting studied. Financial Times frames the move as a setback for Beijing's biotech ambitions, marking the first major Chinese-invented oncology asset to face a US regulatory denial at this stage. Bloomberg and Fierce Pharma emphasize the broader implication: the PD-1xVEGF class, widely viewed as a potential successor to Keytruda combinations, now lacks a clear US pathway.

Summit said it will request a meeting with the FDA to discuss next steps, but no timeline for resubmission or additional trials has been announced. Akeso's China approval for the same asset remains unaffected.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 7h ago.

Who reported it (8)

Questions people are asking

What is ivonescimab?

A bispecific antibody that targets both PD-1 and VEGF, developed by Akeso and licensed to Summit Therapeutics for ex-China rights.

Why did the FDA reject it?

The HARMONi-2 trial did not meet its primary overall survival endpoint in the studied lung cancer population.

Does this affect its status in China?

No, Akeso's approval in China is unchanged.

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Topics

From around our network

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →